Your session is about to expire
← Back to Search
DNA Vaccine
CORVax for COVID-19 (CORVax12 Trial)
Phase 1
Waitlist Available
Research Sponsored by Providence Health & Services
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Women of childbearing potential (WOCBP) must have negative serum or urine pregnancy on each day of vaccine administration.
Males and women of childbearing potential must agree to take appropriate precautions to avoid pregnancy during treatment and through 180 days after last dose of IP.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up month 18
Awards & highlights
CORVax12 Trial Summary
This trial is testing a new vaccine for safety. The vaccine is given with or without a second injection, and researchers are observing how safe it is.
CORVax12 Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowCORVax12 Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ month 18
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~month 18
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Medically Attended Adverse Events (MAAEs)
Toxicity
CORVax12 Trial Design
4Treatment groups
Experimental Treatment
Group I: 2B: Age > 50; CORVax + pIL-12Experimental Treatment3 Interventions
Healthy volunteers age > 50 will receive CORVax + pIL-12
Group II: 2A: Age > 50; CORVaxExperimental Treatment2 Interventions
Healthy volunteers age > 50 will receive CORVax
Group III: 1B: Age 18-50; CORVax + pIL-12Experimental Treatment3 Interventions
Healthy volunteers age 18-50 will receive CORVax + pIL-12
Group IV: 1A: Age 18-50; CORVaxExperimental Treatment2 Interventions
Healthy volunteers age 18-50 will receive CORVax
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
CORVax
2020
Completed Phase 1
~20
IL-12 plasmid
2020
Completed Phase 1
~20
Cliniporator
2020
Completed Phase 1
~20
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Providence Health & ServicesLead Sponsor
115 Previous Clinical Trials
122,507 Total Patients Enrolled
1 Trials studying COVID-19
13 Patients Enrolled for COVID-19
OncoSec Medical IncorporatedIndustry Sponsor
10 Previous Clinical Trials
345 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Share this study with friends
Copy Link
Messenger